Alnylam Pharmaceuticals Inc. (ALNY) Social Stream
ALNYLAM PHARMACEUTICALS INC (ALNY) Price Targets From Analysts
Use the tables below to see what analysts covering ALNYLAM PHARMACEUTICALS INC think about its future price and what recommendations they have for investors and traders.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
---|---|---|---|---|---|---|
2021-11-19 | 17 | $275 | $108 | $200 | $188.55 | 6.07% |
2021-11-22 | 18 | $275 | $108 | $200 | $188.55 | 6.07% |
2021-12-29 | 19 | $275 | $108 | $202.5 | $188.55 | 7.4% |
2022-01-11 | 19 | $275 | $108 | $203.85 | $188.55 | 8.11% |
2022-01-18 | 19 | $275 | $108 | $203.3 | $188.55 | 7.82% |
2022-01-23 | 19 | $350 | $108 | $208.3 | $188.55 | 10.47% |
2022-01-28 | 18 | $350 | $108 | $208.2 | $188.55 | 10.42% |
2022-02-10 | 18 | $350 | $109 | $208.65 | $188.55 | 10.66% |
2022-02-14 | 16 | $350 | $103 | $211.684 | $188.55 | 12.27% |
2022-02-22 | 16 | $350 | $103 | $214.166 | $188.55 | 13.59% |
2022-03-10 | 16 | $350 | $103 | $214.631 | $188.55 | 13.83% |
2022-04-04 | 15 | $350 | $103 | $211.277 | $188.55 | 12.05% |
2022-04-12 | 15 | $400 | $103 | $214.055 | $188.55 | 13.53% |
2022-04-19 | 15 | $400 | $103 | $214.277 | $188.55 | 13.64% |
2022-04-25 | 15 | $400 | $103 | $214.277 | $188.55 | 13.64% |
2022-04-28 | 15 | $400 | $103 | $212.5 | $188.55 | 12.7% |
2022-05-02 | 14 | $400 | $96 | $210.944 | $188.55 | 11.88% |
2022-06-06 | 15 | $430 | $96 | $211.888 | $188.55 | 12.38% |
2022-06-15 | 16 | $430 | $96 | $211.888 | $188.55 | 12.38% |
2022-06-22 | 16 | $430 | $98 | $212.333 | $188.55 | 12.61% |
2022-07-22 | 18 | $430 | $97 | $210.157 | $188.55 | 11.46% |
2022-07-29 | 18 | $430 | $97 | $209.631 | $188.55 | 11.18% |
2022-08-03 | 18 | $430 | $97 | $207.842 | $188.55 | 10.23% |
2022-08-04 | 19 | $430 | $155 | $230.055 | $188.55 | 22.01% |
2022-08-13 | 19 | $430 | $155 | $233.117 | $188.55 | 23.64% |
2022-08-22 | 19 | $430 | $155 | $231.5 | $188.55 | 22.78% |
2022-09-17 | 19 | $430 | $155 | $236.5 | $188.55 | 25.43% |
2022-10-02 | 19 | $430 | $155 | $237.888 | $188.55 | 26.17% |
2022-10-03 | 19 | $430 | $155 | $240.058 | $188.55 | 27.32% |
2022-10-07 | 18 | $430 | $155 | $240.058 | $188.55 | 27.32% |
2022-10-12 | 18 | $430 | $155 | $239.941 | $188.55 | 27.26% |
2022-10-21 | 18 | $430 | $155 | $239.882 | $188.55 | 27.22% |
2022-10-24 | 18 | $430 | $155 | $239.647 | $188.55 | 27.1% |
2022-10-28 | 18 | $430 | $142 | $238.352 | $188.55 | 26.41% |
2022-10-31 | 20 | $430 | $142 | $239.684 | $188.55 | 27.12% |
2022-11-02 | 20 | $415 | $142 | $238.894 | $188.55 | 26.7% |
2022-12-07 | 20 | $415 | $145 | $239.052 | $188.55 | 26.78% |
2022-12-19 | 20 | $415 | $145 | $242.105 | $188.55 | 28.4% |
2022-12-23 | 20 | $415 | $145 | $244.263 | $188.55 | 29.55% |
2023-01-16 | 20 | $415 | $144 | $244.21 | $188.55 | 29.52% |
2023-01-23 | 20 | $415 | $143 | $244.157 | $188.55 | 29.49% |
2023-01-25 | 20 | $415 | $143 | $244.684 | $188.55 | 29.77% |
2023-01-27 | 20 | $415 | $143 | $244.736 | $188.55 | 29.8% |
2023-02-08 | 20 | $415 | $143 | $248.888 | $188.55 | 32% |
2023-02-21 | 21 | $415 | $143 | $251.789 | $188.55 | 33.54% |
2023-02-24 | 22 | $415 | $143 | $252.25 | $188.55 | 33.78% |
2023-02-26 | 22 | $415 | $136 | $250.75 | $188.55 | 32.99% |
2023-03-03 | 21 | $415 | $136 | $250.75 | $188.55 | 32.99% |
The Trend in the Analyst Price Target
Over the past 14 months, ALNY's average price target has gone up $46.9.
ALNY reports an average of 25.35% for its upside potential over the past 48 weeks.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
---|---|---|---|---|---|---|
2022-04-25 | 15 | 400 | 103 | 212.500 | 162.07 | 31.12% |
2022-07-29 | 18 | 430 | 97 | 209.631 | 142.04 | 47.59% |
2022-10-31 | 20 | 430 | 142 | 239.888 | 207.26 | 15.74% |
2023-01-23 | 20 | 415 | 143 | 244.157 | 230.59 | 5.88% |
2023-02-08 | 20 | 415 | 143 | 248.888 | 217.75 | 14.3% |
ALNY Broker Recommendations Summary
Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
---|---|---|---|---|---|---|
1.67 | 13 | 2 | 6 | 0 | 0 | 21 |
The Trend in the Broker Recommendations
Over the past 26 weeks, ALNY's average broker recommendation rating improved by 0.07.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In the context of all US stocks, ALNYLAM PHARMACEUTICALS INC's average analyst price target is greater than 5186.15% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, ALNYLAM PHARMACEUTICALS INC's number of analysts covering the stock is greater than 5425.38% of them.
- To contextualize these metrics, consider that out of stocks in the large market cap category, ALNYLAM PHARMACEUTICALS INC's variance in analysts' estimates is lower than -5125.8% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, ALNYLAM PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is higher than 813.36% of them.
In the Pharmaceutical Products industry, UTHR, BMRN, and NKTR are the three stocks most similar to ALNYLAM PHARMACEUTICALS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for ALNY? Use POWR Ratings for clearer insight into price direction.